StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)

Close on Nov 17, 2026Market cap $91.09MP/E –Yield –

Exagen total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Exagen's total debt was $22.84M at Jun 30, 2026. For fiscal 2025 it was $22.91M, up 13.1% from the year before. The highest annual figure on record is $28.97M in fiscal 2022.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$22.91M+13.1%
FY2024Dec 31, 2024$20.25M+3.8%
FY2023Dec 31, 2023$19.50M-32.7%
FY2022Dec 31, 2022$28.97M+5.4%
FY2021Dec 31, 2021$27.48M+3.1%
FY2020Dec 31, 2020$26.66M+3.1%
FY2019Dec 31, 2019$25.85M+5.0%
FY2018Dec 31, 2018$24.62M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.84M-0.6%
Q1 FY2026Mar 31, 2026$22.87M+9.2%
Q4 FY2025Dec 31, 2025$22.91M+13.1%
Q3 FY2025Sep 30, 2025$22.94M+13.3%
Q2 FY2025Jun 30, 2025$22.98M+13.4%
Q1 FY2025Mar 31, 2025$20.94M+7.2%
Q4 FY2024Dec 31, 2024$20.25M+3.8%
Q3 FY2024Sep 30, 2024$20.25M+4.1%
Q2 FY2024Jun 30, 2024$20.25M+4.3%
Q1 FY2024Mar 31, 2024$19.54M-33.4%
Q4 FY2023Dec 31, 2023$19.50M-32.7%
Q3 FY2023Sep 30, 2023$19.45M-30.5%
Q2 FY2023Jun 30, 2023$19.41M-30.3%
Q1 FY2023Mar 31, 2023$29.35M+6.1%
Q4 FY2022Dec 31, 2022$28.97M+5.4%
Q3 FY2022Sep 30, 2022$28.01M+2.6%
Q2 FY2022Jun 30, 2022$27.83M+2.8%
Q1 FY2022Mar 31, 2022$27.65M+2.9%
Q4 FY2021Dec 31, 2021$27.48M+3.1%
Q3 FY2021Sep 30, 2021$27.29M+3.2%
Q2 FY2021Jun 30, 2021$27.07M+3.1%
Q1 FY2021Mar 31, 2021$26.86M+3.1%
Q4 FY2020Dec 31, 2020$26.66M+3.1%
Q3 FY2020Sep 30, 2020$26.45M+3.0%
Q2 FY2020Jun 30, 2020$26.25M+6.6%
Q1 FY2020Mar 31, 2020$26.05M–
Q4 FY2019Dec 31, 2019$25.85M–
Q3 FY2019Sep 30, 2019$25.68M–
Q4 FY2018Dec 31, 2018$24.62M–

More Exagen figures

See a number that looks wrong?